Cardiovascular Risk and COX-2 Inhibition in Rheumatological Practice

Journal of Human Hypertension - United Kingdom
doi 10.1038/sj.jhh.1001777
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cardiovascular Safety of COX-2 Inhibition: Time to Inform Systems of Postmarketing Surveillance?

Therapy
2005English

Viscum Album-Mediated COX-2 Inhibition Implicates Destabilization of COX-2 mRNA

PLoS ONE
Multidisciplinary
2015English

Inducible COX-2 Dominates Over COX-1 in Prostacyclin Biosynthesis: Mechanisms of COX-2 Inhibitor Risk to Heart Disease

Life Sciences
GeneticsMolecular BiologyPharmacologyBiochemistryMedicineToxicologyPharmaceutics
2011English

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Screening for Cardiovascular Risk in General Practice

BMJ
1994English

COX-2 Gene Promoter Haplotypes and Prostate Cancer Risk

Carcinogenesis
MedicineCancer Research
2004English

Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors

Journal of Experimental Pharmacology
Molecular MedicinePharmacology
2012English

COX-2 Inhibition, Apoptosis, and Chemoprevention by Nonsteroidal Anti-Inflammatory Drugs.

Current Medicinal Chemistry
Organic ChemistryBiochemistryDrug DiscoveryMolecular MedicinePharmacology
2000English

COX-1 and COX-2 Products in the Gut: Therapeutic Impact of COX-2 Inhibitors

Gut
Gastroenterology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy